<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9968">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05686408</url>
  </required_header>
  <id_info>
    <org_study_id>TNX-TI-M201</org_study_id>
    <nct_id>NCT05686408</nct_id>
  </id_info>
  <brief_title>Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)</brief_title>
  <acronym>UPLIFT</acronym>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tonix Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rho, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tonix Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to&#xD;
      evaluate the efficacy, safety, and tolerability of TNX-601 ER monotherapy versus placebo in&#xD;
      patients with Major Depressive Disorder (MDD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2023</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Day 1 and Week 6</time_frame>
    <description>Change from Baseline (Visit 2) in the MADRS total score at Week 6. Scores range from 0 to 60. Lower scores indicate less depression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Severity (CGI-S)</measure>
    <time_frame>Day 1 and Week 6</time_frame>
    <description>Change from Baseline (Visit 2) in the Clinical Global Impression of Severity Scale (CGI-S) score at Week 6. Scores range from 1 to 7. Lower scores indicate less severe illness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sheehan Disability Scale (SDS)</measure>
    <time_frame>Day 1 and Week 6</time_frame>
    <description>Change from Baseline (Visit 2) in the Sheehan Disability Scale (SDS) total score at Week 6. Scores range from 0 to 30. Lower scores indicate less impairment to activities.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Depression</condition>
  <condition>Depressive Disorder</condition>
  <condition>Depressive Symptoms</condition>
  <condition>Depressive Disorder, Major</condition>
  <condition>Depressive Episode</condition>
  <condition>Depression Severe</condition>
  <arm_group>
    <arm_group_label>TNX-601 ER, 39.4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1x TNX-601 ER, 39.4 mg, pill taken orally once daily for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill taken orally once daily for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNX-601 ER</intervention_name>
    <description>Patients will take 1 pill orally once daily for 6 weeks.</description>
    <arm_group_label>TNX-601 ER, 39.4 mg</arm_group_label>
    <other_name>Tianeptine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will take 1 pill orally once daily for 6 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female or male aged 18 to 65 years (inclusive).&#xD;
&#xD;
          -  Have a primary DSM-5 diagnosis of current MDD.&#xD;
&#xD;
               1. The duration of the current MDE must be at least 12 weeks.&#xD;
&#xD;
               2. Without psychotic or catatonic features.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psychiatric History:&#xD;
&#xD;
               1. Diagnosis of DSM-5-defined lifetime bipolar disorder (I, II, or unspecified),&#xD;
                  schizophrenia, schizoaffective disorder, MDD with psychotic features, other&#xD;
                  psychotic disorder, or antisocial personality disorder; current (past month)&#xD;
                  obsessive-compulsive disorder; current (past month) posttraumatic stress&#xD;
                  disorder; current (past 3 months) anorexia nervosa; lifetime opioid or lifetime&#xD;
                  sedative-hypnotic use disorders, as confirmed by the MINI 7.0.2.&#xD;
&#xD;
               2. Diagnosis of borderline personality disorder&#xD;
&#xD;
               3. Patients with comorbid generalized anxiety disorder (GAD), social anxiety&#xD;
                  disorder (SAD), or panic disorder are excluded only if the GAD, SAD, or panic&#xD;
                  disorder is considered the primary psychiatric diagnosis, rather than MDD. (If&#xD;
                  MDD is the primary diagnosis, patients with comorbid GAD, SAD, and panic disorder&#xD;
                  are allowed for randomization).&#xD;
&#xD;
          -  Patients with treatment refractory MDD, ie, previously having in their lifetime failed&#xD;
             â‰¥2 treatments with at least 2 different classes of antidepressants of adequate dose,&#xD;
             duration, and treatment adherence&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Sullivan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tonix Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Project Manager</last_name>
    <phone>212-980-9155</phone>
    <email>ashild.peters@tonixpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashild Peters</last_name>
      <phone>619-991-0553</phone>
      <email>ashild.peters@tonixpharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>January 6, 2023</study_first_submitted>
  <study_first_submitted_qc>January 6, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2023</study_first_posted>
  <last_update_submitted>March 13, 2023</last_update_submitted>
  <last_update_submitted_qc>March 13, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tianeptine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

